# Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib

> **NCT05184595** · NA · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 52 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** Carfilzomib delivered in OH only
- **OTHER:** Carfilzomib delivered in OH and HaH combined

## Key facts

- **NCT ID:** NCT05184595
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2024-10-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184595, "Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05184595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*